Next-Generation Blood Test Panels Show Potential to Replace Liver Biopsy

Key Takeaways

LITMUS confirms what many hepatologists have long suspected: routine individual blood markers cannot reliably identify treatment-eligible patients with at-risk MASH, whereas multi-marker panels can. Alongside an advanced proteomic panel, a pragmatic, GGT-first sequential algorithm also cleared the predefined benchmark required to potentially substitute for liver biopsy in both at-risk MASH and advanced fibrosis—offering a robust, non-invasive alternative for disease staging.

The Needle Standing Between Patient and Prescription

Consider a 58-year-old woman with type 2 diabetes and a body mass index of 34 kg/m², whose ultrasound reveals diffuse hepatic steatosis. Her aminotransferase levels hover just above the upper limit of normal, and her FIB-4 score falls squarely in the indeterminate gray zone. Until recently, the clinical implications of this diagnostic ambiguity were modest; today, the stakes are profoundly different. Resmetirom and semaglutide have garnered regulatory approvals for the treatment of non-cirrhotic MASH with stage F2–F3 fibrosis, and a patient’s eligibility hinges precisely on identifying this disease stage—information that routine blood panels cannot reliably supply^[2]. The traditional answer—a percutaneous biopsy needle advanced through the right intercostal space—carries documented risks of pain, hemorrhage, and sampling error^[3]. To determine whether a less invasive approach could suffice, 1,590 patients across 13 countries underwent liver biopsy to address a…